FORM 4

obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| CIAL OWNERSHIP |
|----------------|
|                |

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name an Franchi  | AI  | 2. Issuer Name <b>and</b> Ticker or Trading Symbol ALEXION PHARMACEUTICALS, INC. [ ALXN] |          |                                  |                                      |   |  |                                 |   | (Check all app     |                       | olicable)  |         | Issuer Owner r (specify  |        |   |   |   |  |
|---|---|--|----------|----------------------------------|--------------------------------------|---|--|---------------------------------|---|--------------------|-----------------------|--|---------|--|--------|---|---|---|--|
| (Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD |   |  |          |                                  |                                      | 3. Date of Earliest Transaction (Month/Day/Year) 02/07/2019 |  |                                 |   |                    |                       |  |         | X Officer (give title Officer (spe below)  EVP, Chief Compliance Officer   |        |   |   | v) .  |  |
| (Street) BOSTON MA 02210 (City) (State) (Zip)                                   |   |  |          |                                  | 4. If                                | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |  |                                 |   |                    |                       |  |         | Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person |        |   |   |   |  |
|   |   | Tabl   | le I - N | lon-Deriv                        | ative                                | Seci  | uritie   | s Ac                            | quire   | d, Di              | sposed o              | f, or B  | enefici | ally C   | )wne   | ed  |   |   |  |
| 1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y               |   |  |          |                                  |                                      | Execution Date,   |  |                                 | 3. Transaction Code (Instr. 8)  4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 and 1) |                    |                       |  |         | ´ Benefici   |        | ities<br>icially<br>d Following   | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |  |
|   |   |  |          |                                  |                                      |   |  |                                 | Code  | v                  | Amount                | (A) or<br>(D)  | Price   |  | Transa | action(s)<br>3 and 4)   |   | (Instr. 4)  |  |
| Common Stock, par value \$.0001 per share 02/07/20                              |   |  |          |                                  |                                      | 019   |  |                                 |   |                    | 1,398(1)              | D  | \$119.  | <b>57</b> <sup>(2)</sup>   | 27,906 |   | D   |   |  |
|   |   | Та   | able II  |                                  |                                      |   |  |                                 |   |                    | osed of,<br>convertib |  |         |  | ned    |   | ,   | ,   |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                             | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year)   | if any   | emed<br>ion Date,<br>//Day/Year) | 4.<br>Transaction<br>Code (Instr. 8) |   | 5. Num<br>of<br>Derive<br>Secun<br>Acqu<br>(A) or<br>Dispo<br>of (D)<br>(Instr.<br>and 5 | ative<br>rities<br>ired<br>osed | 6. Date Expira (Month   | ation D<br>h/Day/` |                       | 7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amoun or Number of Title Shares |         | -  |        | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4) | Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4)               |  |

## **Explanation of Responses:**

- 1. This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$119.43 \$119.57. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

## Remarks:

/s/ Douglas J. Barry, Attorney-02/11/2019 in-Fact for Indrani L. Franchini

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.